

# Supporting Information

## **Green Synthesis of Methoxy-poly(ethylene glycol)-*block*-poly(L-lactide-co-glycolide) Copolymer Using Zinc Proline as a Biocompatible Initiator for Irinotecan Delivery to Colon Cancer *In Vivo***

Prabhanjan S. Giram<sup>a,b</sup>, Julie Tzu-Wen Wang<sup>c\*</sup>, Adam Walters<sup>c</sup>, Priyanka P. Rade<sup>a,b</sup>, Muhammad Akhtar<sup>c,d</sup>, Shunping Han<sup>c</sup>, Farid N. Faruqu<sup>c</sup>, Hend M. Abdel-Bar<sup>c,e</sup>, Baijayantimala Garnaik<sup>a,b\*</sup>, Khuloud T. Al-Jamal<sup>c\*</sup>

<sup>a</sup>Polymer Science and Engineering Division, CSIR-National Chemical Laboratory, Pune-411008, India.

<sup>b</sup>Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.

<sup>c</sup>School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 9NH, UK.

<sup>d</sup>Department of Pharmacy, Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, 63100, Pakistan.

<sup>e</sup>Department of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Egypt.

---

\* To whom correspondence should be addressed.

E-mail: khuloud.al-jamal@kcl.ac.uk; b.garnaik@ncl.res; tzu-wen.wang@kcl.ac.uk

## Supplementary methods

### Characterization of the copolymer

#### *<sup>1</sup>H and <sup>13</sup>C NMR*

Polymers P-1, P-2, and P-3 were dissolved in CDCl<sub>3</sub> at room temperature. <sup>1</sup>H- and <sup>13</sup>C-NMR spectra were recorded using 400 MHz Bruker 400 spectrometer using CDCl<sub>3</sub> as the solvent containing a small amount of the TMS as an internal standard.

#### *ATR-FTIR*

ATR-FTIR spectra of nanoparticles samples were recorded using a (Perkin Elmer IRFTIR spectrometer USA) in 500–4000 cm<sup>-2</sup> wavelength range in an attenuated total reflectance (ATR) mode. The instrument was calibrated with an indium standard before measurements.

#### *GPC*

The molecular weights such as number-average molecular weight [M<sub>n</sub>], weight-average molecular weight [M<sub>w</sub>], and polydispersity [M<sub>w</sub>/M<sub>n</sub>] were determined with respect to polystyrene standards by size-exclusion chromatography on an Agilent Technologies, Polymer Laboratories Gel permeation chromatography (PL-GPC) 220 machine (Santa Clara, CA, USA) at 25 °C, with eluting m-PEG PLGA solutions (10 mg/mL of CHCl<sub>3</sub>) and toluene as an internal standard, and through a series of five 30 cm long Styragel columns with pore sizes of 500, 10<sup>5</sup>, 10<sup>4</sup>, 10<sup>3</sup>, and 100Å. CHCl<sub>3</sub> was used as the mobile phase (flow rate: 1 mL/min), and a refractive index detector was used for the detection of different molecular weight fractions.


#### *MALDI-TOF MS*

MALDI-TOF MS analysis was performed on an AB SCIEX4800 plus MALDI TOF/TOFTM Analyzer. The samples were dissolved in tetrahydrofuran (1mg mL<sup>-1</sup>) and mixed with the matrix (15mg mL<sup>-1</sup> of tetrahydrofuran) and dried on the sample plate. 2, 5-dihydroxybenzoic acid and dithranol were used as the matrix.


### *Transmission Electron Microscopy (TEM)*

TEM imaging of nanoparticles was carried out using (FEI Technai G2 T20) instrument with an acceleration voltage of 200 keV. The TEM sample was prepared by transferring the nanoparticles suspension ( $4 \text{ mg mL}^{-1}$ ) onto a 200-mesh carbon-coated copper grid. Samples were blotted away after 30 min incubation and grids were negatively stained for 10 min at room temperature with freshly prepared, 2 % (w/v) phosphotungstic acid aqueous solution. The grids were then washed twice with distilled water and air-dried before imaging.


## Supplementary figures/tables




**Figure S1. Characterization of mPEG-PLGA copolymer by gel permeation chromatography (GPC) (A) and ATR-FTIR spectrum (B).** The molecular weight of mPEG-PLGA was determined by GPC in which mPEG-PLGA was dissolved in THF with respect to a polystyrene standard.



**Figure S2. MALDI-TOF spectrum of mPEG-PLGA copolymers (A) Fragment of MALDI-TOF (1036-2081) (B) Fragment of MALDI-TOF (2008-3176) (C) Fragment of MALDI-TOF (3051-4261).**



**Figure S3. Transmission electron microscopy of P-NP-Ir.** P-NP-Ir in aqueous suspension was dried on a carbon-coated copper TEM grid and stained with phosphotungstic acid. **(A)** Uniform nanoparticles (scale, 200nm) **(B)** Representative picture of single nanoparticle (scale 20 nm).



**Figure S4. Histological examination of major organs after therapy studies.** CT26 tumour-bearing Balb/c mice were intravenously administered of PBS (control), Ir (free drug), P-NP (empty NP), P-NP-Ir or T-NP-Ir. Each injection dose contained equivalent amount of Ir at  $30 \text{ mg kg}^{-1}$  and P-NP contained matching excipients weight in P-NP-Ir formulation. Mice received a total of 4 injections of the corresponding treatment on day 7, 11, 14 and 17 post-tumor inoculations and sacrificed on day 22. Major organs (heart, lung, liver, spleen and kidney) were excised, formalin-fixed, and stained with H&E. Scale bar,  $50 \mu\text{m}$ .

**Table S1. Optimization of drug loading in T-NPs**

Formulation <sup>a</sup>	Initial drug (mg)	Hydrodynamic diameter (nm) <sup>b,f</sup>	PDI <sup>b</sup>	Zeta potential (mV) <sup>c,f</sup>	Encapsulation Efficiency (EE%) <sup>d,f</sup>	Loading Efficiency (LE%) <sup>e,f</sup>
T-NP	-	109 ± 8.2	0.317	-18.51 ± 1.6	N/A	N/A
	1	118.1 ± 2.7	0.369	-8.71 ± 1.0	33.73 ± 3.8	0.67 ± 0.08
T-NP-Ir	3	125.9 ± 2.1	0.357	-9.1 ± 4.22	62.39 ± 3.4	3.7 ± 0.05
	5	163.8 ± 9.1	0.391	-10.3 ± 6.8	47.04 ± 5.6	4.74 ± 0.02

<sup>a</sup> PLGA 12.5 mg, soya lecithin 12.5 mg, ethanol 1 ml, acetone 1.5 ml, distilled water 5ml, Tween® 80 10mg.

<sup>b</sup> Measured by dynamic light scattering.

<sup>c</sup> Surface charge measured by electrophoresis.

<sup>d</sup> Calculated as percentage of initial drug added, determined by spectrophotometer.

<sup>e</sup> Calculated as mass of incorporated drug divided by the weight of polymer, determined by spectrophotometer.

<sup>f</sup> Expressed as mean ± SD (n=3).

**Table S2. Optimization of drug loading in P-NPs**

Formulation <sup>a</sup>	Initial drug (mg)	Hydrodynamic diameter (nm) <sup>b,f</sup>	PDI <sup>b</sup>	Zeta potential (mV) <sup>c,f</sup>	Encapsulation Efficiency (EE%) <sup>d,f</sup>	Loading Efficiency (LE%) <sup>e,f</sup>
P-NP	-	139.4 ± 2.7	0.321	-14.5 ± 5.2	N/A	N/A
	1	149.1 ± 2.9	0.234	-6.7 ± 1.0	38.30 ± 1.5	0.7 ± 0.05
P-NP-Ir	3	146.9 ± 8.8	0.256	-7.47 ± 6.8	65.75 ± 4.5	3.9 ± 0.08
	5	145.3 ± 7.3	0.261	-9.3 ± 5.1	57.73 ± 0.5	5.7 ± 0.02

<sup>a</sup> PLGA 12.5 mg, soya lecithin 12.5 mg, ethanol 1 ml, acetone 1.5 ml, distilled water 5ml, Pluronic®25mg.

<sup>b</sup> Measured by dynamic light scattering.

<sup>c</sup> Surface charge measured by electrophoresis.

<sup>d</sup> Calculated as percentage of initial drug added, determined by spectrophotometer.

<sup>e</sup> Calculated as mass of incorporated drug divided by the weight of polymer, determined by spectrophotometer.

<sup>f</sup> Expressed as mean ± SD (n=3).